The Supreme Court on June 13 allowed the Food and Drug Administration (FDA) to maintain looser restrictions on mifepristone, otherwise known as the abortion pill, while ruling that a group of pro-life doctors who challenged the agency lacked Article III standing.
The unanimous decision in FDA v. Alliance for Hippocratic Medicine served a temporary win for the FDA and advocates who support the pill, which has come into greater focus after the Court overturned Roe v. Wade.
